Krystal Biotech Inc. (KRYS)
NASDAQ: KRYSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
KRYS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.61B
- P/E (TTM)
- 40.67
- Forward P/E
- 34.83
- EPS (TTM)
- $7.98
- Dividend yield
- None
- 52-week range
- 179.19 – 382.54
- Day range
- 320.20 – 330.44
- Volume / Avg
- 354.15K / 381.19K
- Beta
- —
- Shares outstanding
- 29.60M
- Next earnings
- Nov 2, 2026
52-week range
KRYS stock today
Krystal Biotech (KRYS) closed at $324.57 on Oct 7, down 0.69% (-$2.24), versus the S&P 500's 0.22% decline. Shares are 15.2% below their 52-week high of $382.54, set on Jun 30, 2026 and 81.1% above the 52-week low of $179.19, in the middle of the past year's range. KRYS is up 31.7% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 77.3%.
At 40.7x trailing earnings, Krystal Biotech trades below the peer-group median of 47.5x. Its forward P/E of 34.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Krystal Biotech's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Krystal Biotech
Company profileKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Krish S. Krishnan M.B.A., M.S.
- Headquarters
- Pittsburgh, PA
- Employees
- 295
- IPO year
- 2017
- Website
- krystalbio.com
Financial highlights
Full financialsIn fiscal 2025, Krystal Biotech generated $389.1 million in revenue, up 33.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $204.8 million (+129.7% year over year), for a net margin of 52.6% versus a median of 26.1% in the prior 5 years. Operating margin was 41.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $389.13M | $290.51M | $50.70M | $0 | $0 |
| Growth | +33.94% | +473.02% | — | — | — |
| Net income | $204.83M | $89.16M | $10.93M | $-139.97M | $-69.57M |
| EPS (diluted) | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$392.11+20.81%
- Strong buy 1
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $1.91
- Last reported (Q2 2026)
- Aug 3, 2026
- EPS actual vs est.
- $1.79 vs —
Krystal Biotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PCVXVaxcyte Inc. | 66.96 | +0.39% | $9.96B | vs KRYS |
| QGENQiagen N.V. | 44.79 | -1.88% | $9.25B | vs KRYS |
| TWSTTwist Bioscience Corporation | 155.65 | -6.78% | $10.32B | vs KRYS |
| IBRXImmunityBio Inc. | 9.75 | +0.62% | $10.33B | vs KRYS |
| KYMRKymera Therapeutics Inc. | 108.35 | +2.24% | $8.91B | vs KRYS |
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs KRYS |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs KRYS |
| HALOHalozyme Therapeutics Inc. | 110.79 | +0.98% | $12.57B | vs KRYS |
Indexes, lists and sector
Krystal Biotech stock FAQ
What is Krystal Biotech's stock price today?
KRYS last traded at $324.57 as of Oct 7, 4:00 PM EDT, down 0.69% on the day. Prices are delayed at least 15 minutes.
When is Krystal Biotech's next earnings date?
Krystal Biotech is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $1.91.
What is KRYS's P/E ratio?
KRYS trades at a trailing P/E ratio of 40.67 and a forward P/E of 34.83, compared with a median of 47.5 for its closest peers.
Who is Krystal Biotech's CEO?
Mr. Krish S. Krishnan M.B.A., M.S. is the chief executive officer of Krystal Biotech Inc., which has about 295 employees.
What is the KRYS 52-week high?
The 52-week high for KRYS is $382.54 and the 52-week low is $179.19. The stock is currently 15.2% below its high.